Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
AORT reported a Form 144 disclosing planned sales of common stock tied to a restricted stock vesting event. The filing lists 1,731 shares associated with the vesting on 02/20/2026 and shows prior sales of 4,572 shares on 12/08/2025 for $203,081.38.
The sale activity is routed through Fidelity Brokerage Services LLC (address shown) and is recorded in the filing as compensation-related vesting. Timing and detailed plan-of-distribution mechanics beyond the vesting date are not included in the excerpt.
James Mackin reported proposed sales of common stock under a Form 144. The filing lists 20,962 shares to be sold in connection with restricted stock vesting on 02/20/2026. The filing also shows prior sales of 30,921 shares on 12/02/2025 for $1,408,736.02 and 30,921 shares on 12/03/2025 for $1,405,693.40.
Artivion, Inc. is a cardiac and vascular surgery company focused on treating aortic disease through medical devices and implantable human tissues. It operates in two segments: Medical Devices (aortic stent grafts, On‑X mechanical heart valves, surgical sealants, synthetic grafts, other devices) and Preservation Services (cardiac and vascular tissue preservation).
The company markets globally across North America, EMEA, APAC, and Latin America, using direct sales teams and distributors, and relies on organ procurement organizations and tissue banks for human tissues. It faces intense competition from large device makers and other tissue processors, as well as regulatory, quality, and supply‑chain risks, including dependence on single‑ and sole‑source suppliers and evolving US, European, UK, Swiss, and other regulatory regimes.
Artivion invests heavily in innovation, spending about $31.0 million on research and development in 2025, or roughly 7% of revenue, to advance new aortic stent graft systems, expand indications and geographies for existing products like On‑X valves and BioGlue, and support clinical trials for products such as AMDS and the NEXUS family.
Nomura Asset Management International Inc. and Nomura Investment Management Business Trust report beneficial ownership of 2,613,471 shares of Artivion, Inc. common stock on a Schedule 13G as of 12/31/2025. This represents 5.5% of the common stock, based on 47,374,939 shares outstanding as of October 31, 2025.
The firms report shared voting and dispositive power over all 2,613,471 shares, with no sole voting or dispositive power. They certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Artivion.
Artivion Inc. received an updated Schedule 13G/A (Amendment No. 7) from Macquarie Group Limited, Macquarie Management Holdings Inc., and Macquarie Investment Management Business Trust regarding Artivion’s common shares. As of 12/31/2025, the Macquarie reporting entities disclose beneficial ownership of 0 common shares, representing 0.00% of the class, with no sole or shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Artivion.
Artivion, Inc. reported strong growth for the fourth quarter and full year 2025, moving from losses to profitability. Fourth quarter GAAP revenue rose to $116.0 million from $97.3 million, with GAAP net income of $2.4 million versus a prior-year net loss of $(16.5) million. Full year 2025 revenue increased to $441.3 million from $388.5 million, and GAAP net income improved to $9.8 million from a net loss of $(13.4) million. Non-GAAP net income reached $8.6 million in the quarter and $29.7 million for the year, while adjusted EBITDA grew to $22.7 million in the quarter and $89.6 million for 2025. Growth was driven by aortic stent grafts, On-X valves, and steady preservation services, supported by positive clinical data and progress on regulatory filings. For 2026, Artivion guides to revenue of $486–$504 million and adjusted EBITDA of $105–$110 million, implying double‑digit revenue growth and faster adjusted EBITDA growth.